However, knockdown of ADAM17 or treatment with anti-ADAM17 antibody MEDI3622 resulted in regression of pancreatic tumors, accompanied by down-regulated EGFR/STAT3 signaling, increased cytotoxic T cells, and decreased granulocyte-like medullary inhibitory cells in mouse models of pancreatic cancer (212). This evidence concerns the gene ADAM17 and pancreatic neoplasm.